Exelixis
EXEL
#1495
Rank
$14.35 B
Marketcap
$57.94
Share price
-0.80%
Change (1 day)
40.63%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): $3.30

According to Exelixis's latest financial reports the company's current EPS (TTM) is $3.30. In 2025 the company made an earnings per share (EPS) of $2.89.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)$3.3014.19%
2025$2.89
2023$0.6514.61%
2022$0.57-22.97%
2021$0.74100%
2020$0.37-65.09%
2019$1.06-53.91%
2018$2.30333.96%
2017$0.53-260.61%
2016-$0.33-58.75%
2015-$0.80-42.45%
2014-$1.395.3%
2013-$1.32

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
$8.73 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
$0.76-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
$16.22 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
$1.90-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
$1.27-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
$4.54 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
$3.20-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-$14.22-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-$0.84-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA